Condition: Head and Neck Squamous Cell Carcinoma (HNSCC) · Non-small Cell Lung Cancer (NSCLC) · Esophageal Cancer · Sponsor: Tanabe Pharma America, Inc.
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.
This description comes directly from the study's public registry record.
Clinical Trials Information Desk, to prevent miscommunication, · Please E-mail · information.US@mb.tanabe-pharma.com
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| National Cancer Center Hospital | Chuo-Ku, Tokyo, Japan | Recruiting |
| National Cancer Center Hospital East | City, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06943521